NASDAQ:VKTX Viking Therapeutics Q2 2026 Earnings Report $37.95 +1.57 (+4.32%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$37.88 -0.07 (-0.18%) As of 07:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Viking Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$1.21Beat/MissN/AOne Year Ago EPSN/AViking Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AViking Therapeutics Announcement DetailsQuarterQ2 2026Date7/29/2026TimeAfter Market ClosesConference Call DateWednesday, July 29, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Viking Therapeutics Earnings HeadlinesKuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law FirmJuly 21 at 4:41 PM | prnewswire.comHead-To-Head Analysis: Capstone Therapeutics (NASDAQ:CAPS) vs. Viking Therapeutics (NASDAQ:VKTX)July 21 at 3:49 AM | americanbankingnews.comOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warning for AI investors - and a specific prediction about what the number-one investment of the next decade will be. Green started his career on Wall Street four decades ago and retired in his 40s. He believes a major shift in the AI trade is coming - and that most investors won't hear about it until it's too late.July 22 at 1:00 AM | The Oxford Club (Ad)Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1July 18, 2026 | fool.comShould You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes.July 18, 2026 | fool.comViking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to NoteJuly 17, 2026 | finance.yahoo.comSee More Viking Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Viking Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viking Therapeutics and other key companies, straight to your email. Email Address About Viking TherapeuticsViking Therapeutics (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders. The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions. Viking conducts Phase 2 clinical trials for these candidates, evaluating safety, tolerability and efficacy across multiple patient populations. Viking Therapeutics maintains operations across the United States, engaging with clinical research sites to enroll patients in its ongoing studies. The company also collaborates with academic institutions and regulatory agencies to advance trial designs and biomarker strategies that support its drug development objectives. Under the leadership of President and Chief Executive Officer David A. Woodhouse, Viking has built a management team with extensive experience in endocrinology, metabolic disease and biopharmaceutical development. The company’s strategic focus remains on progressing its pipeline through clinical milestones and exploring opportunities to extend its proprietary technology platform into additional indications.View Viking Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3M's Redemption Arc: Can Q2 Earnings Change the Narrative?Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of EarningsConfidence Is Back, But Earnings Show the Consumer Is Being PickyIndustrial and Utility Giants Boost Dividends as Data Center Tailwinds BuildIREN’s $2.8 Billion AI Contract Haul Changes the Stock’s StoryBuy, Hold, or Wait: 3 Small-Cap Stocks Telling Different StoriesIs Domino's Stock Serving Up a Buying Opportunity? Upcoming Earnings RTX (7/23/2026)Lockheed Martin (7/23/2026)Newmont (7/23/2026)Intel (7/23/2026)Nokia (7/23/2026)Relx (7/23/2026)SAP (7/23/2026)STMicroelectronics (7/23/2026)T-Mobile US (7/23/2026)Comfort Systems USA (7/23/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
